Standard vs high-dose radiotherapy for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial compares standard-dose and higher-dose radiotherapy given along with chemotherapy in people with rectal cancer. The goal is to see whether a higher dose can improve rectal cancer outcomes while keeping the rectum functioning and avoiding too much harm.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed rectal adenocarcinoma (a type of rectal cancer found on biopsy/pathology)
- A tumor board (MDT) has said you may be able to have rectal surgery after treatment
- Your rectal tumor is in the cT1 to cT3 range and you have MRI results that match the trial size/location limits (tumor up to 4.5 cm and its lowest edge at or below the peritoneal reflection)
- You are an adult (18 or older) with overall health that is good enough for treatment (performance status 0–2)
- You must be able to take both radiotherapy and capecitabine, with blood tests and organ function within required ranges
- You cannot have had prior pelvic radiation, distant spread (metastases), or have a current colostomy/ileostomy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of giving radiation therapy for advanced rectal cancer, combined with a chemotherapy pill and an immunotherapy drug. One approach uses a shorter course of radiation before surgery, and the other uses a longer course; researchers want to see which is more effective and safer.
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests whether combining chemotherapy with high-dose radiation guided by MRI (a special scan) can better treat low rectal cancer. It may help shrink the tumor and improve local control while targeting the tumor more precisely.
This trial tests a short course of radiation therapy combined with chemotherapy for people with stage II or III rectal cancer. It’s designed to see whether this approach is safe and effective before or around cancer surgery.
This trial compares two approaches for early-stage rectal cancer: chemotherapy plus local surgery versus standard chemoradiotherapy. It aims to see if less intensive treatment can work just as well, reducing side effects.
Hear when a new Cancer of Rectum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.